2,514
Views
15
CrossRef citations to date
0
Altmetric
Editorial

The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma

, , , , , , & show all
Pages 231-234 | Received 02 Sep 2016, Accepted 03 Jan 2017, Published online: 18 Jan 2017

References

  • Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed Res Int. 2015;2015:341430. Epub 2015 12 10.
  • Colla S, Storti P, Donofrio G, et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010;24:1967–1970. Epub 2010 09 03.
  • Storti P, Bolzoni M, Donofrio G, et al. Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 2013;27:1697–1706. Epub 2013 01 25.
  • Corbet C, Feron O. Metabolic and mind shifts: from glucose to glutamine and acetate addictions in cancer. Curr Opin Clin Nutr Metab Care. 2015;18:346–353. Epub 2015 05 24.
  • Bhutia YD, Babu E, Ramachandran S, et al. Amino acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75:1782–1788. Epub 2015 04 10.
  • Bolzoni M, Chiu M, Accardi F, et al. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood. 2016;128:667–679. Epub 2016 06 09.
  • Bajpai R, Matulis SM, Wei C, et al. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene. 2016;35:3955–3964. Epub 2015 12 08.
  • Nakaya M, Xiao Y, Zhou X, et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity. 2014;40:692–705. Epub 2014 05 06.
  • Broer A, Rahimi F, Broer S. Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells. J Biol Chem. 2016;291:13194–13205. Epub 2016 04 30.
  • Wang Q, Beaumont KA, Otte NJ, et al. Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer. 2014;135:1060–1071. Epub 2014 02 18.
  • Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619–634. Epub 201.
  • Jeon YJ, Khelifa S, Ratnikov B, et al. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell. 2015;27:354–369. Epub 2015 03 12.
  • Chiu M, Tardito S, Barilli A, et al. Glutamine stimulates mTORC1 independent of the cell content of essential amino acids. Amino Acids. 2012;43:2561–2567. Epub 2012 05 09.
  • Csibi A, Lee G, Yoon SO, et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr Biol. 2014;24:2274–2280. Epub 2014 09 16.
  • Jewell JL, Kim YC, Russell RC, et al. Differential regulation of mTORC1 by leucine and glutamine. Science. 2015;347:194–198. Epub 2015 01 09.
  • Nguyen TV, Lee JE, Sweredoski MJ, et al. Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon. Mol Cell. 2016;61:809–820. Epub 2016 03 19.
  • Mates JM, Segura JA, Martin-Rufian M, et al. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med. 2013;13:514–534. Epub 2012 09 01.
  • Perez-Gomez C, Campos-Sandoval JA, Alonso FJ, et al. Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem J. 2005;386:535–542. Epub 2004 10 22.
  • Chiu M, Tardito S, Pillozzi S, et al. Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer. 2014;111:1159–1167. Epub 2014 07 30.
  • Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24:450–465. Epub 2013 10 08.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.